Tumor characteristics and prognosis in familial breast cancer
Grazia Arpino(University of Naples Federico II), Sabino De Placido, Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Caterina Condello(University of Naples Federico II), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Matilde Pensabene(University of Naples Federico II), Rossella Lauria, Maurizio Montella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), I. Cerillo, Raffaella Ruocco(University of Naples Federico II)
Cited by 37
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282